Autolus moves forward with novel CAR-T therapy candidate

23 April 2018

UK-based immuno-oncology startup Autolus has pulled the trigger on a licensing agreement to acquire global rights from UCL Business to develop and commercialize a novel CAR-T cell therapy targeting B cell malignancies.

Autolus was launched in 2015 with a £30 million ($45.5 million) commitment from investment company Syncona, together with UCL Business, the wholly-owned technology transfer company of University College London.

Designated AUTO1, the investigational therapy modifies a patient's T cells to express a novel CD19-specific CAR designed to reduce side effects related to cytokine release syndrome (CRS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK